Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|62|3|784-791

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.62, Iss.3, 2015-09, pp. : 784-791

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

By  

CANCER, Vol. 120, Iss. 2, 2014-01 ,pp. : 229-237

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 108-114

Karger

Access to resources Recommend Favorite

Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series

By  

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 265-272

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy

By  

Oncology, Vol. 81, Iss. 2, 2011-10 ,pp. : 98-103

Karger

Access to resources Recommend Favorite